Caribou Biosciences, Inc. (CRBU): restructuring charge — Caribou cuts 32% workforce, discontinues lupus/AML trials, cash runway to H2 2027

Caribou Biosciences, Inc.

Workforce reduction of 47 employees (~32%), expected completion by Q2 2025.
Preliminary cash, equivalents & marketable securities of $212.5M as of March 31, 2025.
Discontinued GALLOP (lupus), AMpLify (AML) trials & preclinical research to focus on CB-010 & CB-011.
Estimated restructuring costs of $2.5-3.5M, primarily severance and trial wind-down.
Cash runway extended one year to H2 2027; CB-010 & CB-011 data readouts planned for H2 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Caribou Biosciences, Inc. announced a restructuring with charges of approximately $2.5 million to $3.5 million in total affecting GALLOP phase 1 clinical trial for CB-010 in lupus, AMpLify phase 1 clinical trial for CB-012, and preclinical research (47 employees, or approximately 32% of the Company).

Type: restructuring
Charge: approximately $2.5 million to $3.5 million in total
Affected area: GALLOP phase 1 clinical trial for CB-010 in lupus, AMpLify phase 1 clinical trial for CB-012, and preclinical research
Headcount: 47 employees, or approximately 32% of the Company

Exact text from the filing

half of 2027. In connection with the strategic pipeline prioritization and the workforce reduction, the Company currently estimates it will incur expenses of approximately $2.5 million to $3.5 million in total, consisting primarily of cash severance costs, benefits, and transition support services for impacted employees, and future costs to wind down its GALLOP

View on SEC.gov

Browse all restructurings & charges →

Caribou Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001619856-25-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.